Literature DB >> 19342643

Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.

Derese Getnet1, Charles H Maris, Edward L Hipkiss, Joseph F Grosso, Timothy J Harris, Hung-Rong Yen, Tullia C Bruno, Satoshi Wada, Adam Adler, Robert W Georgantas, Chunfa Jie, Monica V Goldberg, Drew M Pardoll, Charles G Drake.   

Abstract

Tumors express a wide variety of both mutated and nonmutated Ags. Whether these tumor Ags are broadly recognized as self or foreign by the immune system is currently unclear. Using an autochthonous prostate cancer model in which hemagglutinin (HA) is specifically expressed in the tumor (ProHA x TRAMP mice), as well as an analogous model wherein HA is expressed in normal tissues as a model self-Ag (C3HA(high)), we examined the transcriptional profile of CD4 T cells undergoing Ag-specific division. Consistent with our previous data, transfer of Ag-specific CD4 T cells into C3HA(high) resulted in a functionally inactivated CD4 T cell profile. Conversely, adoptive transfer of an identical CD4 T cell population into ProHA x TRAMP mice resulted in the induction of a regulatory phenotype of the T cell (Treg) both at the transcriptional and functional level. Interestingly, this Treg skewing was a property of even early-stage tumors, suggesting Treg induction as an important tolerance mechanism during tumor development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342643      PMCID: PMC3082355          DOI: 10.4049/jimmunol.0803400

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  CD8+ T cell contraction is controlled by early inflammation.

Authors:  Vladimir P Badovinac; Brandon B Porter; John T Harty
Journal:  Nat Immunol       Date:  2004-07-11       Impact factor: 25.606

3.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

4.  Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Authors:  Marianne A Mihalyo; Adam T Hagymasi; Aaron M Slaiby; Erin E Nevius; Adam J Adler
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

5.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

6.  Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.

Authors:  Adam T Hagymasi; Aaron M Slaiby; Marianne A Mihalyo; Harry Z Qui; David J Zammit; Leo Lefrancois; Adam J Adler
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

Review 7.  Autochthonous mouse models for prostate cancer: past, present and future.

Authors:  W J Huss; L A Maddison; N M Greenberg
Journal:  Semin Cancer Biol       Date:  2001-06       Impact factor: 15.707

8.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

9.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

10.  CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.

Authors:  A J Adler; D W Marsh; G S Yochum; J L Guzzo; A Nigam; W G Nelson; D M Pardoll
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

View more
  21 in total

Review 1.  Immunotherapy for prostate cancer: biology and therapeutic approaches.

Authors:  Edward Cha; Lawrence Fong
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

2.  Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes.

Authors:  Julie L Mitchell; Amara Seng; Thomas M Yankee
Journal:  Immunology       Date:  2016-09-20       Impact factor: 7.397

3.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

Review 4.  Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.

Authors:  Peter A Savage; Daniel S Leventhal; Sven Malchow
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

Review 5.  Prostate cancer as a model for tumour immunotherapy.

Authors:  Charles G Drake
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

6.  A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.

Authors:  Derese Getnet; Joseph F Grosso; Monica V Goldberg; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Nicholas M Durham; Edward L Hipkiss; Kristin J Pyle; Satoshi Wada; Fan Pan; Drew M Pardoll; Charles G Drake
Journal:  Mol Immunol       Date:  2010-03-11       Impact factor: 4.407

Review 7.  Immunotherapy for prostate cancer: an emerging treatment modality.

Authors:  Charles G Drake
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

8.  Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.

Authors:  Michal Kuczma; Magdalena Kopij; Iwona Pawlikowska; Cong-Yi Wang; Grzegorz A Rempala; Piotr Kraj
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

Review 9.  Cancer and the Immune System: Basic Concepts and Targets for Intervention.

Authors:  Drew Pardoll
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

10.  Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Authors:  Haydn Thomas Kissick; Martin George Sanda; Laura Kathleen Dunn; Mohamed Simo Arredouani
Journal:  Cancer Immunol Immunother       Date:  2013-10-23       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.